Form 4: Denali Director Acquires Shares and Options

Denali Therapeutics Inc. Director Timothy Van Hauwermeiren reported the acquisition of common stock and stock options.

Summary

• Timothy Van Hauwermeiren, a Director of Denali Therapeutics Inc. (DNLI), acquired 10,632 shares of common stock in the form of Restricted Stock Units (RSUs) on November 4, 2025.
• The RSUs were acquired at a price of $0 per share.
• He also acquired stock options for 31,897 shares of common stock with an exercise price of $14.92, granted on November 4, 2025.
• The RSU award vests over a four-year period, with 1/4th of the shares vesting on each anniversary of the grant date, contingent on continued service as a non-employee director.
• The stock options vest 25% on November 4, 2026, and an additional 1/48th of the shares vest each month thereafter, also contingent on continued service as a non-employee director.
• The stock options have an expiration date of November 4, 2034.

Sentiment

Score: 6

Explanation: The acquisition of shares and options by a director is generally a positive signal of confidence in the company's future, though it represents routine compensation for non-employee directors rather than an open-market purchase.

Positives

• A director acquiring shares and options can signal confidence in the company's future prospects and alignment of interests with shareholders.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the director's acquisition of equity as a positive signal of confidence in the company's future performance and alignment of interests.

Next Steps

• Continued vesting of 10,632 Restricted Stock Units over a four-year period, subject to continued service.
• Continued vesting of 31,897 stock options, with 25% vesting on November 4, 2026, and monthly thereafter, subject to continued service.

Key Dates

Keywords

Denali Therapeutics, DNLI, Form 4, Insider Transaction, Director, Stock Option, Restricted Stock Unit, Equity Compensation, Biotechnology